Updated Guidance for COVID-19 Convalescent Plasma Use from the FDA and AABB With a lack of effective treatments for COVID-19, the U.S. FDA issued Emergency Use Authorization to use convalescent plasma to… February 17, 2021
Platelet Extracellular Vesicles Formed During Storage May Be Causative Agents in Non-Antibody-Mediated TRALI Transfusion-related acute lung-injury (TRALI) is a rare but potentially fatal complication of plasma transfusions affecting 1 in 10,000 transfusions and… February 9, 2021
Antigen Density on Surface of RBCs a Factor in RBC Clearance in Incompatible Transfusions Select patients with chronic anemia and sickle cell disease require recurrent transfusions and are at risk for alloimmunization and potentially… February 3, 2021
Epitope Matched HLA Platelets Are Noninferior to Standard Matched HLA Platelets Alloimmunization to human leukocyte antigens (HLA) leads to platelet refractoriness, defined as decreased post-transfusion platelet count increments (PCIs), and is… January 27, 2021
RHD Genotyping in Transfusion Practice Could Identify Novel RHD Alleles and Conserve D-negative Blood Partial D phenotypes (with altered D epitopes) and weak D phenotypes (with a reduced number of D antigens present on… January 20, 2021
Early Convalescent Plasma Therapy Helps Prevent Severe COVID-19 COVID-19 convalescent plasma administered late in the course of disease has not shown clear benefits, but some studies suggest that… January 12, 2021
Higher Hemoglobin Transfusion Thresholds Do Not Improve Outcomes in Preterm Infants Within the last decade, lower hemoglobin transfusion thresholds have been found to be safe and effective for most patient subpopulations. … January 5, 2021
